We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Updated advice for healthcare professionals is available, after conclusion of a review of the safety of idelalisib, including the risk of infection.
There are new interim treatment recommendations for idelalisib for chronic lymphocytic leukaemia and follicular lymphoma in light of new findings from clinical trials outside its currently authorised drug combinations or indicated populations.
A summary of safety letters sent to healthcare professionals in August 2016
A. Menarini Farmaceutica Internazionale Srl is recalling a specific batch as a precautionary measure due to the distribution of Invokana 300mg in Northern Ireland in packaging intended for the Greek market.
Employment Appeal Tribunal Judgment of Mrs Justice Eady on 18 April 2024.
medac GmbH (t/a medac Pharma LLP) is recalling the product for the batch specified in this notification due to particles detected during long-term stability tests.
Information on the reporting, investigation and management of acute flaccid paralysis (AFP) and acute flaccid myelitis (AFM).
Product Safety Report for Esapharma Movate Steroid Cream presenting a serious chemical risk.
Check the tariff classification for surface-active preparation for washing the skin and the hair (gel 2-in-1).
Product Safety Report for SIVOP Parfums & Cosmétiques Clair-Liss Lightening Body Cream presenting a serious chemical risk.
Product Recall for Vincenza Jewellery Pave Zircon Initial Cord Bracelet presenting a serious chemical risk.
Guidance for the veterinary pharmaceutical industry on the production and submission of the Summary of Product Characteristics (SPCs) and product literature mock-ups.
Report a problem ('adverse incident') with a medical device or medicine to MHRA using the Yellow Card Scheme
In March 2016, letters were sent regarding SGLT2 inhibitors, insulin lispro, natalizumab, noradrenaline, radium-223 dichloride, aflibercept and idelalisib.
Safety leaflet on topical corticosteroids and withdrawal reactions to help patients and their carers to use these medicines safely.
Information on variants of the SARS-CoV-2 virus.
Product Safety Report for Skin Gard Lightening Lotion presenting a serious chemical risk.
This guide is about infections that occur in people who inject drugs (PWID).
Fifteen additional synthetic opioids are now under the strictest controls to prevent drug related deaths and ensure anyone caught supplying them faces tough penalties.
How the MHRA makes decisions on when a product is a medical device (borderline products), and which risk class should apply to a medical device.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.